

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES, NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

Initial public offer of Equity Shares (as defined below) on the main board of the Stock Exchanges (defined below) in compliance with Chapter II of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended.

PUBLIC ANNOUNCEMENT



AKUMS DRUGS AND PHARMACEUTICALS LIMITED



(Please scan this QR code to view the DRHP)

Our Company was incorporated as a public company, limited by shares, under the Companies Act, 1956, as amended, in the name of 'Akums Drugs and Pharmaceuticals Limited', pursuant to a certificate of incorporation dated April 19, 2004 issued by the Registrar of Companies, Delhi and Haryana in New Delhi ("RoC"). Our Company received a certificate of commencement of business issued by the RoC dated May 13, 2004.

Registered Office: 304, Mohan Place, LSC Saraswati Vihar, Delhi - 110 034, India

Corporate Office: Plot no. 131 to 133, Block C, Mangolpuri, Ind. Area, Phase 1, Delhi - 110 083, India

Telephone: +91 11 6904 1000; Contact person: Dharamvir Malik, Company Secretary and Compliance Officer

E-mail: cs@akums.net; Website: www.akums.in; Corporate Identity Number: U24239DL2004PLC125888

NOTICE TO INVESTORS ("NOTICE")

INITIAL PUBLIC OFFER OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹ 2 EACH ("EQUITY SHARES") OF AKUMS DRUGS AND PHARMACEUTICALS LIMITED ("COMPANY" OR "ISSUER") FOR CASH AT A PRICE OF ₹ [•] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [•] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹ [•] MILLION COMPRISING A FRESH ISSUE OF UP TO [•] EQUITY SHARES AGGREGATING UP TO ₹ 6,800 MILLION BY OUR COMPANY ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 18,998,365 EQUITY SHARES AGGREGATING UP TO ₹ [•] MILLION ("OFFERED SHARES") BY THE SELLING SHAREHOLDERS, COMPRISING UP TO 2,145,965 EQUITY SHARES AGGREGATING UP TO ₹ [•] MILLION BY SANJEEV JAIN, UP TO 2,145,965 EQUITY SHARES AGGREGATING UP TO ₹ [•] MILLION BY SANDEEP JAIN (TOGETHER THE "PROMOTER SELLING SHAREHOLDERS") AND UP TO 14,306,435 EQUITY SHARES AGGREGATING UP TO ₹ [•] MILLION BY RUBY QC INVESTMENT HOLDINGS PTE. LTD. (THE "INVESTOR SELLING SHAREHOLDER") (THE PROMOTER SELLING SHAREHOLDERS AND THE INVESTOR SELLING SHAREHOLDER, COLLECTIVELY REFERRED TO AS THE "SELLING SHAREHOLDERS") ("OFFER FOR SALE", TOGETHER WITH THE FRESH ISSUE, THE "OFFER").

Potential Bidders may note the following as a corrigendum cum addendum ("Addendum") to the draft red herring prospectus dated February 10, 2024, filed our Company with the Securities and Exchange Board of India and Stock Exchanges ("DRHP"):

On May 29, 2024, Ruby QC Holdings Pte. Ltd., the Investor Selling Shareholder ("Ruby QC"), has waived one of its exit right (the "Buy-back Waiver") under Clause 8.10(ii)(b) of the shareholders' agreement dated October 3, 2019 ("SHA"), entered into by and amongst our Company, its individual Promoters, namely, Sandeep Jain, Sanjeev Jain, and Ruby QC read with the Waiver cum Amendment Agreement dated February 9, 2024 and undertaking dated May 15, 2024 to the SHA and such right shall be of no further force or effect without any further act or deed required by any party to the SHA. This Buy-back Waiver effected in relation to the provisions of the SHA shall also be deemed to be a waiver under the corresponding provisions of the Articles of Association of our Company.

Accordingly, pursuant to the Buy-back Waiver, Ruby QC's exit right under Clause 8.10(ii)(b) of the SHA has been waived in its entirety with effect from May 29, 2024. Accordingly, the Company is no longer required to buy-back the Equity Shares held by Ruby QC in the event the Company and/or its Promoters are unable to facilitate an exit for Ruby QC.

Please note that since the buy-back option under Clause 8.10(ii)(b) of the SHA was part of a waterfall mechanism and could only be triggered if the Offer was not consummated by December 31, 2024 and a secondary sale was not facilitated by the Company and its Promoters of the Equity Shares held by Ruby QC, irrespective of the Buy-back Waiver, the Company's obligation to buy-back the Equity Shares held by Ruby QC was not in operation as on the date of filing of the DRHP, i.e., February 10, 2024.

Based on above, we confirm that the Company, any of its Directors and the Book Running Lead Managers have not entered into any buy-back arrangements for purchase of Equity Shares from any person.

Please note that this Addendum does not reflect all the changes that have occurred between the date of filing of the DRHP with the SEBI and the Stock Exchanges and the date hereof, and accordingly, does not include all the changes and/or updates that will be included in the RHP and the Prospectus. The information in this Addendum supplements and updates the information in the DRHP and the above changes are to be read in conjunction with the DRHP and accordingly, relevant references in the DRHP stand updated pursuant to this Addendum. Potential Bidders should read this Addendum in conjunction with the DRHP.

This Addendum which has been filed with SEBI and the Stock Exchanges shall be made available to the public for comments, if any, for a period of at least 21 days, from the date of such filing with SEBI and the Stock Exchanges and will be available on their website www.sebi.gov.in, the websites of the Stock Exchanges i.e., www.nseindia.com, www.bseindia.com, the website of the Company i.e. www.akums.in and the website of the BRLMs, i.e., ICICI Securities Limited at www.icicisecurities.com, Axis Capital Limited at www.axiscapital.co.in, Citigroup Global Markets India Private Limited at www.online.citibank.co.in and Ambit Private Limited at www.ambit.co.

Capitalized terms used in this Addendum shall, unless the context otherwise requires, have the meaning ascribed to them in the DRHP.

BOOK RUNNING LEAD MANAGERS

1 ICICI Securities	AXIS CAPITAL	citi	AMBIT Acumen at work
ICICI Securities Limited ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025 Tel: +91 22 6807 7100 E-mail: akums ipo@icicisecurities.com Investor grievance e-mail: customercare@icicisecurities.com Website: www.icicisecurities.com Contact Person: Namrata Ravasia / Harsh Thakkar SEBI Registration No.: INM000011179	Axis Capital Limited 1 st Floor, Axis House, C-2 Wadia International Centre, Pandurang Budhkar Marg, Worli, Mumbai 400 025, Maharashtra, India Tel: +91 22 4325 2183 E-mail: akums.ipo@axiscap.in Investor grievance e-mail: complaints@axiscap.in Website: www.axiscapital.co.in Contact Person: Akash Aggarwal / Jigar Jain SEBI Registration No.: INM000012029	Citigroup Global Markets India Private Limited 1202, 12 th Floor, First International Financial Centre, G-Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 098, Maharashtra, India Tel: +91 22 6175 9999 E-mail: akums.ipo@citi.com Investor Grievance ID: investors.cgmib@citi.com Website: www.online.citibank.co.in/rhmn/citigroupglobalscreen1.htm Contact Person: Abhishek Mawandiya SEBI Registration Number: INM000010718	Ambit Private Limited Ambit House, 449, Senapati Bapat Marg, Lower Parel, Mumbai 400 013 Maharashtra, India Tel: +91 22 6623 3030 E-mail: akums.ipo@ambit.co Investor Grievance E-mail: customerservice@ambit.co Website: www.ambit.co Contact person: Siddhesh Deshmukh SEBI registration number: INM000010585

REGISTRAR TO THE OFFER

LINK Intime	Link Intime India Private Limited C-101, 1 st Floor, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai 400 083, Maharashtra, India Tel: +91 810 811 4949; E-mail: akumsdrugs.ipo@linkintime.co.in; Website: www.linkintime.co.in Investor Grievance ID: akumsdrugs.ipo@linkintime.co.in; Contact Person: Shanti Gopalkrishnan SEBI Registration Number: INR000004058
--------------------	---

For AKUMS DRUGS AND PHARMACEUTICALS LIMITED
On behalf of the Board of Directors

Place: New Delhi
Date: May 31, 2024

Sd/-
Dharamvir Malik
Company Secretary & Compliance Officer

AKUMS DRUGS AND PHARMACEUTICALS LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the DRHP dated February 10, 2024, with SEBI on February 11, 2024. The DRHP shall be available on the website of SEBI at www.sebi.gov.in, the websites of the Stock Exchanges i.e., BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, and the websites of the BRLMs, i.e., ICICI Securities Limited, Axis Capital Limited, Citigroup Global Markets India Private Limited and Ambit Private Limited at www.icicisecurities.com, www.axiscapital.co.in, www.online.citibank.co.in/rhmn/citigroupglobalscreen1.htm and www.ambit.co, respectively. Potential Bidders should note that investment in equity shares involves a high degree of risk and for details relating to such risk, please see the section titled "Risk Factors" of the RHP, once filed. Potential Bidders should not rely on the DRHP filed with SEBI for making any investment decision and must rely on their own examination of our Company and the Offer, including the risks involved.

This announcement does not constitute an invitation or offer of securities for sale in any jurisdiction. The Equity Shares offered in the Offer have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended ("U.S. Securities Act") and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (a) within the United States solely to "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act) pursuant to Section 4(a) of the U.S. Securities Act, and (b) outside the United States in offshore transactions as defined in and in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of securities in the United States.

Adiactors